-

08:38:47 AM

PPBT Stock News

PPBT - Purple Biotech Ltd

03/24/23 7:00 AM

Nasdaq : PPBT

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a

RHEA-AI

neutral

03/16/23 7:00 AM

Nasdaq : PPBT

clinical trial

Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study

Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company

RHEA-AI

neutral

02/14/23 7:01 AM

Nasdaq : PPBT

clinical trial

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion

RHEA-AI

neutral

02/08/23 7:12 AM

Nasdaq : PPBT

earnings

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing

RHEA-AI

neutral

02/02/23 7:00 AM

Nasdaq : PPBT

acquisition

Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer

Purple Biotech Ltd. (NASDAQ/TASE:

RHEA-AI

neutral

01/03/23 7:00 AM

Nasdaq : PPBT

Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments

As a subsidiary of Clalit Healthcare Services, Israel’s largest HMO, Mor Research Applications brings Purple Biotech first access to research conducted at 14 hospitals The collaboration with Mor Research Applications has the potential to accelerate Purple Biotech’s future pipeline expansion in

RHEA-AI

very positive

11/15/22 7:00 AM

Nasdaq : PPBT

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis

Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a

RHEA-AI

neutral

11/10/22 7:00 AM

Nasdaq : PPBT

conferences

Purple Biotech to Present at the Jefferies London Healthcare Conference

Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcome

RHEA-AI

neutral

11/08/22 7:53 AM

Nasdaq : PPBT

earnings

Purple Biotech Reports Third Quarter 2022 Financial Results

Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and

RHEA-AI

neutral

11/02/22 7:37 AM

Nasdaq : PPBT

management

Purple Biotech Appoints Lior Fhima as Chief Financial Officer

Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of

RHEA-AI

very positive